September 2022
1. STANFIELD BA, Bravo FJ, Dixon DA, Chouljenko VN, et al
   Cross protective efficacy of the Non-Neurotropic live attenuated herpes simplex virus type 1 vaccine VC-2 is enhanced by intradermal vaccination and deletion of glycoprotein G.
   Vaccine. 2022 Sep 13. pii: S0264-410X(22)01119.
   

   >> Share

   
   August 2021
2. GORANDER S, Honda-Okubo Y, Backstrom M, Baldwin J, et al
   A truncated glycoprotein G vaccine formulated with Advax-CpG adjuvant provides protection of mice against genital herpes simplex virus 2 infection.
   Vaccine. 2021 Aug 26. pii: S0264-410X(21)01098.
   

   >> Share

   
   April 2021
3. CARR DJJ, Berube AN, Filiberti A, Gmyrek GB, et al
   Lack of neonatal Fc receptor does not diminish the efficacy of the HSV-1 0DeltaNLS vaccine against ocular HSV-1 challenge.
   Vaccine. 2021 Apr 1. pii: S0264-410X(21)00379.
   

   >> Share

   
   October 2020
4. LATOURETTE PC 2ND, Awasthi S, Desmond A, Pardi N, et al
   Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine.
   Vaccine. 2020 Oct 8. pii: S0264-410X(20)31261.
   

   >> Share

   
   September 2019
5. BERNSTEIN DI, Cardin RD, Bravo FJ, Hamouda T, et al
   Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes.
   Vaccine. 2019 Sep 9. pii: S0264-410X(19)31153.
   

   >> Share

   
   May 2019
6. AWASTHI S, Hook LM, Swaminathan G, Cairns TM, et al
   Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants.
   Vaccine. 2019 May 29. pii: S0264-410X(19)30705.
   

   >> Share

   
   September 2017
7. SCHIFFER JT, Gottlieb SL
   Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.
   Vaccine. 2017 Sep 25. pii: S0264-410X(17)31273.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share